PFO closure trials reverse course (2012-2017)
Randomized trials reported between 2012 and 2013 found no clear benefit from closing a patent foramen ovale after a stroke, and the procedure was used inconsistently. In September 2017, the New England Journal of Medicine published the CLOSE and REDUCE results along with long-term RESPECT data. Together they showed fewer recurrent strokes after closure in carefully selected patients.
The FDA had approved the first closure device for reducing recurrent stroke in 2016, and a second followed in 2018.
A 2020 American Academy of Neurology practice advisory said clinicians may recommend closure for selected patients under 60, after shared decision making.
Closure is now an approved, guideline-endorsed option, which turns finding a PFO into a clinically useful step and puts pressure on the diagnostic bottleneck.
